IDEXX Laboratories, Inc. $IDXX Shares Acquired by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 42,865 shares of the company’s stock after buying an additional 7,734 shares during the quarter. Mediolanum International Funds Ltd’s holdings in IDEXX Laboratories were worth $23,880,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Annis Gardner Whiting Capital Advisors LLC increased its stake in IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock worth $67,000 after acquiring an additional 21 shares during the last quarter. Gryphon Financial Partners LLC lifted its stake in shares of IDEXX Laboratories by 44.3% in the 1st quarter. Gryphon Financial Partners LLC now owns 472 shares of the company’s stock valued at $265,000 after purchasing an additional 145 shares during the last quarter. Gallacher Capital Management LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at $371,000. Angeles Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 17.3% during the 1st quarter. Angeles Wealth Management LLC now owns 1,383 shares of the company’s stock worth $777,000 after purchasing an additional 204 shares during the period. Finally, Financiere des Professionnels Fonds d investissement inc. grew its holdings in shares of IDEXX Laboratories by 236.1% during the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 1,210 shares of the company’s stock worth $680,000 after purchasing an additional 850 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on IDXX shares. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDXX opened at $567.44 on Friday. The stock’s 50-day moving average price is $554.49 and its 200 day moving average price is $599.94. IDEXX Laboratories, Inc. has a 12-month low of $513.02 and a 12-month high of $769.98. The firm has a market cap of $44.76 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 3.10 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.